INS and diabetes mellitus: Type 2 diabetes mellitus is perceived as a progressive disease with continuous pancreatic beta-cell dysfunction necessitating insulin therapy (IT) within 10 to 12 years of diagnosis.1 2 IT improves glycemic control and reduces microvascular complications, but does not significantly benefit cardiovascular disease (CVD) morbidity and mortality.1 3 4 IT is associated with adverse outcomes including weight gain, hypoglycemia, and reduced quality of life (QoL).5